title: Blood transfusion and in-hospital outcomes in anemic patients with myocardial infarction undergoing percutaneous coronary intervention.
abstract: Studies have shown poor prognostic implications of anemia in patients with myocardial infarction (MI) and in patients undergoing percutaneous coronary intervention (PCI). The impact of blood transfusion in these populations remains controversial. The objective of this study was to examine the effect of transfusion on in-hospital mortality in anemic patients undergoing PCI for MI. Data from 67,051 PCIs (June 1, 1997 to January 31, 2004) were prospectively collected in a multicenter registry (Blue Cross Blue Shield of Michigan Cardiovascular Consortium). Of these, 4,623 patients who were classified as anemic according to the World Health Organization criteria underwent PCI within 7 days of presentation with acute MI. A propensity score for being transfused was estimated for each patient, and propensity matching and a prediction model for in-hospital death were developed. The average age was 67.8 years, 57.7% of patients were men, and 22.3% of patients received a transfusion during hospitalization. Transfused patients, compared to nontransfused patients, were more likely to be older, female, have lower preprocedure hemoglobin levels, more comorbidities, and a higher unadjusted in-hospital mortality rate (14.52% vs. 3.01%, p < 0.0001). After adjustment for comorbidities and propensity for transfusion, blood transfusion was associated with a higher risk of in-hospital mortality (adjusted odds ratio = 2.02, 95% confidence interval 1.47-2.79, p < 0.0001). In anemic patients undergoing PCI for MI, transfusion was associated with an increased crude and adjusted rate of in-hospital mortality. A randomized controlled trial is needed to determine the value of transfusion and the ideal transfusion criteria.
authors.affiliation: Division of Cardiology, University of Michigan Medical Centers, Ann Arbor, USA.
authors.forename: Sandeep M
authors.initials: SM
authors.lastname: Jani
authors.forename: Dean E
authors.initials: DE
authors.lastname: Smith
authors.forename: David
authors.initials: D
authors.lastname: Share
authors.forename: Eva
authors.initials: E
authors.lastname: Kline-Rogers
authors.forename: Sanjaya
authors.initials: S
authors.lastname: Khanal
authors.forename: Michael J
authors.initials: MJ
authors.lastname: O'Donnell
authors.forename: Julius
authors.initials: J
authors.lastname: Gardin
authors.forename: Mauro
authors.initials: M
authors.lastname: Moscucci
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D015906:Angioplasty, Balloon, Coronary; D000925:Anticoagulants / Q000008:administration & dosage / Q000009:adverse effects*; D001803:Blood Transfusion / Q000706:statistics & numerical data*; D005260:Female; D006470:Hemorrhage / Q000139:chemically induced / Q000401:mortality / Q000517:prevention & control*; D006760:Hospitalization; D006801:Humans; D008297:Male; D008824:Michigan / Q000453:epidemiology; D009203:Myocardial Infarction / Q000188:drug therapy / Q000401:mortality* / Q000628:therapy; D017063:Outcome Assessment, Health Care; D011183:Postoperative Complications / Q000139:chemically induced / Q000401:mortality / Q000517:prevention & control*; D011446:Prospective Studies
chemical_list: D000925:Anticoagulants